X4 Pharmaceuticals

IPO

With Rare Resolve.

Public · Boston, United States · Founded 2014 · $446.8M raised

Employees
51–200
Founded
2014
Business Model
B2B
Total Funding
$446.8M
Last Round
$155.3M Series COct 2025
Rounds
7
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

X4 Pharmaceuticals is a clinical-stage biopharmaceutical company developing and commercializing innovative therapies for rare diseases of the immune system. Its lead asset, mavorixafor (XOLREMDI®), has received U.S. FDA approval for its first indication in WHIM syndrome, with ongoing Phase 3 trials in chronic neutropenic disorders. X4 is headquartered in Boston and trades on Nasdaq under XFOR.

Summary

X4 Pharmaceuticals is a Biotech company based in Boston, United States, founded in 2014. It has raised $446.8M in total across 7 rounds, most recently a $155.3M Series C round in Oct 2025. Investors include Coastlands Capital, New Enterprise Associates and Bain Capital Life Sciences.

Tech & App Stack

5 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

Series CPublic OfferingOct 2025
$155.3M

Sign up to see all 8 events

Funding: Seed through Series C. Amounts, valuations, and investors where available.

Investors

Similar Companies

Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech, Drug Discovery
Extension RoundTotal funding$1.2BNov 2021
OricIPO

San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...

South San Francisco, United States51–200Biotech, Healthcare
Private EquityTotal funding$647.0MFeb 2026
Neumora TherapeuticsIPO

Clinical-stage biopharmaceutical developing precision medicines targeting novel mechanisms to tre...

Watertown, United States51–200Biotech, Drug Discovery
Series BTotal funding$612.0MOct 2022
AsymchemIPO

Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...

Tianjin, China5001–10000Biotech, Drug Discovery
Private EquityTotal funding$2.3BFeb 2020
Paratek PharmaceuticalsAcquired

Paratek Pharmaceuticals develops and delivers innovative treatments for serious infectious diseas...

Boston, United States201–500Biotech, Healthcare
ConvertibleTotal funding$1.8BApr 2018
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

X4 Pharmaceuticals on Indexed.vc
<a href="https://indexed.vc/companies/x4-pharmaceuticals"><img src="https://indexed.vc/api/badge/company/x4-pharmaceuticals" alt="X4 Pharmaceuticals on Indexed.vc" width="260" height="76" /></a>